Research & Literature

Hepatopancreatobiliary manifestations of inflammatory bowel disease.

Nakamura K, Ito T, Kotoh K, et al.

Clinical journal of gastroenterology 2012; (5(1)):1-8 doi:10.1007/s12328-011-0282-1.

Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis.

Wannhoff A, Rupp C, Friedrich K, et al.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015; (13(13)):2372-9.

Bile duct basement membrane thickening in primary sclerosing cholangitis.

Colling R, Verrill C, Fryer E, et al.

Histopathology 2016; (68(6)):819-24 doi:10.1111/his.12857.

New Thoughts on Immunoglobulin G4-Related Sclerosing Cholangitis.

Smit WL, Culver EL, Chapman RW

Clinics in liver disease 2016; (20(1)):47-65.

Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.

Rossi RE, Conte D, Massironi S

European journal of gastroenterology & hepatology 2016; (28(2)):123-31 doi:10.1097/MEG.0000000000000532.

Diagnosis, Differential Diagnosis, and Epidemiology of Primary Sclerosing Cholangitis.

Ponsioen CY

Digestive diseases (Basel, Switzerland) 2015; (33 Suppl 2()):134-9 doi:10.1159/000440823.

Pathogenesis and Management of Pruritus in PBC and PSC.

Kremer AE, Namer B, Bolier R, et al.

Digestive diseases (Basel, Switzerland) 2015; (33 Suppl 2()):164-75 doi:10.1159/000440829.

Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis.

Cheung AC, Patel H, Meza-Cardona J, et al.

Digestive diseases and sciences 2016; (61(6)):1692-9 doi:10.1007/s10620-015-4013-1.

Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD.

Fevery J, Van Steenbergen W, Van Pelt J, et al.

Alimentary pharmacology & therapeutics 2016; (43(5)):612-20 doi:10.1111/apt.13516.

A review of the medical treatment of primary sclerosing cholangitis in the 21st century.

Goode EC, Rushbrook SM

Therapeutic advances in chronic disease 2016; (7(1)):68-85 doi:10.1177/2040622315605821.

IgG4-Related Sclerosing Cholangitis.

Nakazawa T, Shimizu S, Naitoh I

Seminars in liver disease 2016; (36(3)):216-28 doi:10.1055/s-0036-1584321.

Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis.

Ehlken H, Wroblewski R, Corpechot C, et al.

PloS one 2016; (11(10)):e0164224 doi:10.1371/journal.pone.0164224.

Pharmacological interventions for pruritus in adult palliative care patients.

Siemens W, Xander C, Meerpohl JJ, et al.

The Cochrane database of systematic reviews 2016; (11()):CD008320 doi:10.1002/14651858.CD008320.pub3.

Clinical relevance of combined anti-mitochondrial M2 detection assays for primary biliary cirrhosis.

Han E, Jo SJ, Lee H, et al.

Clinica chimica acta; international journal of clinical chemistry 2017; (464()):113-117 doi:10.1016/j.cca.2016.11.021.

Small Duct Primary Sclerosing Cholangitis in Association With Hepatitis C Virus Infection: A Case Report.

Nayudu SK, Kumbum K, Balar B, et al.

Gastroenterology research 2011; (4(1)):39-41 doi:10.4021/gr282w.

The Microbiome and Primary Sclerosing Cholangitis.

Ali AH, Carey EJ, Lindor KD

Seminars in liver disease 2016; (36(4)):340-348 doi:10.1055/s-0036-1594007.

An update on cancer risk and surveillance in primary sclerosing cholangitis.

Horsley-Silva JL, Rodriguez EA, Franco DL, Lindor KD

Liver international : official journal of the International Association for the Study of the Liver 2017; (37(8)):1103-1109 doi:10.1111/liv.13354.

Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.

Palmela C, Peerani F, Castaneda D, et al.

Gut and liver 2018; (12(1)):17-29 doi:10.5009/gnl16510.

Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.

Saffioti F, Gurusamy KS, Hawkins N, et al.

The Cochrane database of systematic reviews 2017; (3()):CD011343 doi:10.1002/14651858.CD011343.pub2.

Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner.

Trivedi PJ, Tickle J, Vesterhus MN, et al.

Gut 2018; (67(6)):1135-1145 doi:10.1136/gutjnl-2016-312354.

Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011.

Sørensen JØ, Nielsen OH, Andersson M, et al.

Liver international : official journal of the International Association for the Study of the Liver 2018; (38(3)):532-541 doi:10.1111/liv.13548.

An update on the physiopathology and therapeutic management of cholestatic pruritus in children.

Thébaut A, Debray D, Gonzales E

Clinics and research in hepatology and gastroenterology 2018; (42(2)):103-109 doi:10.1016/j.clinre.2017.08.007.

Endoscopic Management of Primary Sclerosing Cholangitis.

Barkin JA, Levy C, Souto EO

Annals of hepatology 2017; (16(6)):842-850 doi:10.5604/01.3001.0010.5274.

Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis.

Martin EF, Levy C

Seminars in liver disease 2017; (37(4)):305-313 doi:10.1055/s-0037-1608655.

New therapies target the toxic consequences of cholestatic liver disease.

Jansen PLM

Expert review of gastroenterology & hepatology 2018; (12(3)):277-285 doi:10.1080/17474124.2018.1424538.

Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning.

Eaton JE, Vesterhus M, McCauley BM, et al.

Hepatology (Baltimore, Md.) 2020; (71(1)):214-224 doi:10.1002/hep.30085.

No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis.

Ponsioen CY, Arnelo U, Bergquist A, et al.

Gastroenterology 2018; (155(3)):752-759.e5 doi:10.1053/j.gastro.2018.05.034.

Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Sedki M, Levy C

Current gastroenterology reports 2018; (20(7)):29 doi:10.1007/s11894-018-0635-8.

Primary sclerosing cholangitis: A review and update.

Tabibian JH, Bowlus CL

Liver research (Beijing, China) 2017; (1(4)):221-230 doi:10.1016/j.livres.2017.12.002.

IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis.

Tanaka A

Gut and liver 2019; (13(3)):300-307 doi:10.5009/gnl18085.

Immunoglobulin G4 Sclerosing Cholangitis: An Unusual Cause of Obstructive Jaundice-Case Report and Literature Review.

Shrestha P, Le B, Wagner B, et al.

Case reports in rheumatology 2018; (2018()):9602373 doi:10.1155/2018/9602373.

PSC-IBD: specific phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis.

Bajer L, Wohl P, Drastich P

Vnitrni lekarstvi 2018; (64(6)):659-664.

IgG4-Related Sclerosing Cholangitis Involving the Intrahepatic Bile Ducts Diagnosed with Liver Biopsy.

Thinesen MT, Schaffalitzky de Muckadell OB, Detlefsen S

Case reports in pathology 2018; (2018()):2309293 doi:10.1155/2018/2309293.

Correlation between quantitative liver and spleen volumes and disease severity in primary sclerosing cholangitis as determined by Mayo risk score.

Khoshpouri P, Ameli S, Ghasabeh MA, et al.

European journal of radiology 2018; (108()):254-260 doi:10.1016/j.ejrad.2018.10.006.

Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis.

Deneau MR, Mack C, Abdou R, et al.

Hepatology communications 2018; (2(11)):1369-1378 doi:10.1002/hep4.1251.

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.

Goode EC, Clark AB, Mells GF, et al.

Hepatology (Baltimore, Md.) 2019; (69(5)):2120-2135 doi:10.1002/hep.30479.

Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis.

Wannhoff A, Brune M, Knierim J, et al.

Alimentary pharmacology & therapeutics 2019; (49(6)):769-778 doi:10.1111/apt.15146.

Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation.

Steenstraten IC, Sebib Korkmaz K, Trivedi PJ, et al.

Alimentary pharmacology & therapeutics 2019; (49(6)):636-643 doi:10.1111/apt.15148.

Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence.

Mertz A, Nguyen NA, Katsanos KH, Kwok RM

Annals of gastroenterology 2019; (32(2)):124-133 doi:10.20524/aog.2019.0344.

Comparison of Sertraline with Rifampin in the treatment of Cholestatic Pruritus: A Randomized Clinical Trial.

Ataei S, Kord L, Larki A, et al.

Reviews on recent clinical trials 2019; (14(3)):217-223 doi:10.2174/1574887114666190328130720.

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review.

Bowlus CL, Lim JK, Lindor KD

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2019; (17(12)):2416-2422 doi:10.1016/j.cgh.2019.07.011.

The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis.

Cazzagon N, Lemoinne S, El Mouhadi S, et al.

The American journal of gastroenterology 2019; (114(12)):1878-1885 doi:10.14309/ajg.0000000000000461.

Primary sclerosing cholangitis with increased immunoglobulin G4 levels: A case report.

Chen QL, Zhong R, Zhang XX, et al.

Medicine 2019; (98(50)):e18411 doi:10.1097/MD.0000000000018411.

Small Duct Primary Sclerosing Cholangitis: An Underdiagnosed Cause of Chronic Liver Disease and Cirrhosis.

Deliwala S, Sundus S, Haykal T, et al.

Cureus 2020; (12(3)):e7298 doi:10.7759/cureus.7298.

Magnetic resonance imaging features of small-duct primary sclerosing cholangitis.

Kozaka K, Sheedy SP, Eaton JE, et al.

Abdominal radiology (New York) 2020; (45(8)):2388-2399 doi:10.1007/s00261-020-02572-w.

Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC).

Ringe KI, Bergquist A, Lenzen H, et al.

European journal of radiology 2020; (129()):109101 doi:10.1016/j.ejrad.2020.109101.

Liver Elastography in Primary Sclerosing Cholangitis Patients Using Three Different Scanner Systems.

Mjelle AB, Fossdal G, Gilja OH, Vesterhus M

Ultrasound in medicine & biology 2020; (46(8)):1854-1864 doi:10.1016/j.ultrasmedbio.2020.03.025.

Review of primary sclerosing cholangitis with increased IgG4 levels.

Manganis CD, Chapman RW, Culver EL

World journal of gastroenterology 2020; (26(23)):3126-3144 doi:10.3748/wjg.v26.i23.3126.

Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease.

de Krijger M, Visseren T, Wildenberg ME, et al.

Journal of translational autoimmunity 2020; (3()):100054 doi:10.1016/j.jtauto.2020.100054.

[Autoimmune liver diseases].

Fischer HP, Goltz D

Der Pathologe 2020; (41(5)):444-456 doi:10.1007/s00292-020-00807-7.

Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis.

Fejfar T, Vaňásek T, Hůlek P

Vnitrni lekarstvi 2020; (66(5)):287-300.

Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis.

Eaton JE, Welle CL, Bakhshi Z, et al.

Hepatology (Baltimore, Md.) 2021; (73(5)):1868-1881 doi:10.1002/hep.31575.

Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.

Gao RY, Shearn CT, Orlicky DJ, et al.

Mucosal immunology 2021; (14(2)):479-490 doi:10.1038/s41385-020-00347-6.

An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen.

Morley VJ, Kinnear CL, Sim DG, et al.

eLife 2020; (9()).

NAFLD exacerbates cholangitis and promotes cholangiocellular carcinoma in mice.

Maeda S, Hikiba Y, Fujiwara H, et al.

Cancer science 2021; (112(4)):1471-1480 doi:10.1111/cas.14828.

Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis.

Mazhar A, Russo MW

Alimentary pharmacology & therapeutics 2021; (53(7)):774-783 doi:10.1111/apt.16296.

Cholestasis-Associated Pruritus and Its Pruritogens.

Langedijk JAGM, Beuers UH, Oude Elferink RPJ

Frontiers in medicine 2021; (8()):639674 doi:10.3389/fmed.2021.639674.

Primary sclerosing cholangitis.

Rabiee A, Silveira MG

Translational gastroenterology and hepatology 2021; (6()):29 doi:10.21037/tgh-20-266.

Safety considerations for the management of cholestatic itch.

Trivella J, Levy C

Expert opinion on drug safety 2021; (20(8)):915-924 doi:10.1080/14740338.2021.1915984.

Fibrotic Events in the Progression of Cholestatic Liver Disease.

Wu H, Chen C, Ziani S, et al.

Cells 2021; (10(5)) doi:10.3390/cells10051107.

Endoscopic retrograde cholangiopancreatography and intraductal ultrasonography in the diagnosis of autoimmune pancreatitis and IgG4-related sclerosing cholangitis.

Naitoh I, Nakazawa T

Journal of medical ultrasonics (2001) 2021; (48(4)):573-580 doi:10.1007/s10396-021-01114-1.

Non-invasive diagnosis and follow-up of primary sclerosing cholangitis.

Chazouillères O, Potier P, Bouzbib C, et al.

Clinics and research in hepatology and gastroenterology 2022; (46(1)):101775 doi:10.1016/j.clinre.2021.101775.

Systematic Review of Prognostic Models Compared to the Mayo Risk Score for Primary Sclerosing Cholangitis.

Schmeltzer PA, Russo MW

Journal of clinical medicine 2021; (10(19)) doi:10.3390/jcm10194476.

Patient-Predicted Outcomes Are Associated with Quality of Life in Patients with Primary Sclerosing Cholangitis.

Henson JB, Helzberg JH, Muir AJ

Digestive diseases and sciences 2022; (67(12)):5483-5492 doi:10.1007/s10620-022-07482-z.

Impact on follow-up strategies in patients with primary sclerosing cholangitis.

Bergquist A, Weismüller TJ, Levy C, et al.

Liver international : official journal of the International Association for the Study of the Liver 2023; (43(1)):127-138 doi:10.1111/liv.15286.

Serological biomarkers for management of primary sclerosing cholangitis.

Tornai D, Ven PL, Lakatos PL, Papp M

World journal of gastroenterology 2022; (28(21)):2291-2301 doi:10.3748/wjg.v28.i21.2291.

[Gastrointestinal endoscopy in the diagnosis and treatment of biliary liver disease].

Liang XY, Ding HG

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2022; (30(7)):690-695 doi:10.3760/cma.j.cn501113-20220427-00222.

An orally administered drug prevents selection for antibiotic-resistant bacteria in the gut during daptomycin therapy.

Morley VJ, Sim DG, Penkevich A, et al.

Evolution, medicine, and public health 2022; (10(1)):439-446 doi:10.1093/emph/eoac035.

Berberine Ursodeoxycholate for the Treatment of Primary Sclerosing Cholangitis: The Search for the Elusive Pharmacologic Holy Grail Will Need to Continue.

Yoshida EM

The American journal of gastroenterology 2022; (117(11)):1762-1763 doi:10.14309/ajg.0000000000001999.

Recent advances in surveillance colonoscopy for dysplasia in inflammatory bowel disease.

Na SY, Moon W

Clinical endoscopy 2022; (55(6)):726-735 doi:10.5946/ce.2022.132.

Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid.

Hochberg JT, Sohal A, Handa P, et al.

JHEP reports : innovation in hepatology 2023; (5(6)):100729 doi:10.1016/j.jhepr.2023.100729.

Anti-integrin αvβ6 autoantibodies in patients with primary sclerosing cholangitis.

Yoshida H, Shiokawa M, Kuwada T, et al.

Journal of gastroenterology 2023; (58(8)):778-789 doi:10.1007/s00535-023-02006-6.

The role of serology, liver function tests and imaging in screening of primary sclerosing cholangitis: the HelPSCreen score.

Barner-Rasmussen N, Sjöblom N, Arola J, et al.

Scandinavian journal of gastroenterology 2023; (58(12)):1491-1498 doi:10.1080/00365521.2023.2233038.

Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis.

Onofrio F, Zheng K, Xu C, et al.

Hepatology communications 2023; (7(8)) doi:10.1097/HC9.0000000000000219.

Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options.

Hatami B, Pasharavesh L, Sharifian A, Zali MR

Gastroenterology and hepatology from bed to bench 2023; (16(3)):259-269 doi:10.22037/ghfbb.v16i2.2589.

Noninvasive prognostic models, imaging, and elastography to predict clinical events in primary sclerosing cholangitis: A review.

Russo MW

World journal of hepatology 2023; (15(9)):1013-1020 doi:10.4254/wjh.v15.i9.1013.

Treatment of Primary Sclerosing Cholangitis Including Transplantation.

Wheless WH, Russo MW

Clinics in liver disease 2024; (28(1)):171-182 doi:10.1016/j.cld.2023.07.008.

Diagnostic value of anti-mitochondrial antibody in patients with primary biliary cholangitis: A systemic review and meta-analysis.

Xu Q, Zhu W, Yin Y

Medicine 2023; (102(45)):e36039 doi:10.1097/MD.0000000000036039.

Primary Sclerosing Cholangitis: Diagnostic Criteria.

Cazzagon N, Sarcognato S, Catanzaro E, et al.

Tomography (Ann Arbor, Mich.) 2024; (10(1)):47-65 doi:10.3390/tomography10010005.

A Review of IgG4-related Sclerosing Cholangitis (IgG4-SC).

Khoury NC, Birk JW

Journal of clinical gastroenterology 2024; (58(10)):963-969 doi:10.1097/MCG.0000000000001984.

Novel preclinical developments of the primary sclerosing cholangitis treatment landscape.

Sohal A, Kowdley KV

Expert opinion on investigational drugs 2024; (33(4)):335-345 doi:10.1080/13543784.2024.2330738.

Carbohydrate Antigen (CA 19-9) Surge: Unraveling the Enigma of Elevated Levels in the Setting of Benign Etiologies.

Ansari N, Ozgur SS, Besada D, et al.

Cureus 2024; (16(4)):e57469 doi:10.7759/cureus.57469.

From random to precise: updated colon cancer screening and surveillance for inflammatory bowel disease.

Fatakhova K, Rajapakse R

Translational gastroenterology and hepatology 2024; (9()):27 doi:10.21037/tgh-23-36.

Dye-based chromoendoscopy detects more neoplasia than white light endoscopy in patients with primary sclerosing cholangitis and IBD.

Motta RV, Gupta V, Hartery K, et al.

Endoscopy international open 2024; (12(11)):E1285-E1294 doi:10.1055/a-2437-8102.

An Unusual Case of Intrahepatic Stone Masquerading as Cholangiocarcinoma.

Williams AS, Sikes MA, Liu S

ACG case reports journal 2025; (12(2)):e01607 doi:10.14309/crj.0000000000001607.

Liver transplantation for cholestatic liver diseases: Timing and disease recurrence.

Cançado GGL, Deeb M, Gulamhusein AF

Hepatology (Baltimore, Md.) 2025; (82(4)):1016-1035 doi:10.1097/HEP.0000000000001268.

Endoscopic management of primary sclerosing cholangitis.

Mizuno S, Uchida Y, Ando S, et al.

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2025; (37(7)):723-732 doi:10.1111/den.15010.

Performance of the Mayo Risk Score in Predicting Transplant and Mortality in a Single-Center U.S. Cohort of Primary Sclerosing Cholangitis.

Kahan T, Marenco-Flores A, Amaris NR, et al.

Journal of clinical medicine 2025; (14(6)) doi:10.3390/jcm14062098.

Fatigue and itch severity in patients with PBC and PSC: Prospective analysis of two large cohorts.

Kruk B, Raszeja-Wyszomirska J, Krawczyk M, Milkiewicz P

European journal of clinical investigation 2025; (55(7)):e70041 doi:10.1111/eci.70041.

Endoscopic retrograde cholangiopancreatography: A comprehensive review as a single diagnostic tool.

Papaefthymiou A, Landi R, Arvanitakis M, et al.

Best practice & research. Clinical gastroenterology 2025; (74()):101976 doi:10.1016/j.bpg.2025.101976.

MR imaging and cholangiography show suboptimal performance for diagnosing ductal cholangiocarcinoma in primary sclerosing cholangitis patients.

Buhot Q, Bui Q, Chekir H, et al.

European radiology 2025; (35(10)):6544-6553 doi:10.1007/s00330-025-11606-0.

Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registry.

Dean R, Yazdanfar M, Zepeda J, et al.

Hepatology communications 2025; (9(5)) doi:10.1097/HC9.0000000000000703.

Primary sclerosing cholangitis: what is new in the therapeutic landscape.

Curto A, Cristoferi L, Carbone M, et al.

Current opinion in immunology 2025; (96()):102613 doi:10.1016/j.coi.2025.102613.

Aramchol attenuates fibrosis in mouse models of biliary fibrosis and blocks the TGFβ-induced fibroinflammatory mediators in cholangiocytes.

Aseem SO, Wang J, Kalaiger MF, et al.

Hepatology communications 2025; (9(8)) doi:10.1097/HC9.0000000000000748.

Donor-Recipient Race Mismatch Is Associated with Lower Survival After Liver Transplantation for Primary Sclerosing Cholangitis.

Russo MW, Wheless W, Cherikh WS, et al.

Journal of clinical medicine 2025; (14(15)) doi:10.3390/jcm14155441.

Longitudinal Comparison of Currently Used Risk Scores for Prognostication of Primary Sclerosing Cholangitis (PSC) in a Hungarian Bicenter PSC Cohort.

Ven PL, Tornai D, Toth B, et al.

Diagnostics (Basel, Switzerland) 2025; (15(17)) doi:10.3390/diagnostics15172166.

Quantitative MRCP as Part of Primary Sclerosing Cholangitis Standard of Care in the National Health Service in England: A Feasibility Assessment Among Hepatologists.

Shumbayawonda E, Bajre M, Eadle D, et al.

Healthcare (Basel, Switzerland) 2025; (13(20)) doi:10.3390/healthcare13202630.

Risk of Intestinal and Extraintestinal Malignancies in Inflammatory Bowel Disease With and Without Primary Sclerosing Cholangitis.

Al Ta'ani O, Alsakarneh S, Shaukat A, et al.

Digestive diseases and sciences 2025; doi:10.1007/s10620-025-09593-9.

Pruritus and health-related quality of life in chronic liver disease: a longitudinal, survey-based cohort study.

Gungabissoon U, Hunnicutt J, McDermott EJ, et al.

BMJ open gastroenterology 2025; (12(1)) doi:10.1136/bmjgast-2025-001809.

Clinical Outcomes in Patients with Primary Sclerosing Cholangitis With and Without Inflammatory Bowel Disease.

Ibrahim A, Rockey DC

Digestive diseases and sciences 2026; doi:10.1007/s10620-026-09699-8.

A multinational survey assessing the impact and burden of pruritus on patients with primary sclerosing cholangitis.

Kowdley KV, Safer R, Gomel R, et al.

Hepatology communications 2026; (10(3)) doi:10.1097/HC9.0000000000000904.